Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Medtronic PLC Stock Advances 3.9%, Outperforms Peers

Medtronic PLC Stock Advances 3.9%, Outperforms Peers

Dow JonesDow Jones2026/10/12 20:34

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Medtronic PLC advanced 3.9% to $91.93 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.4% to 51,850.55 and the S&P 500 Index falling 0.1% to 7,807.24.

This was the stock's third consecutive day of gains.

Medtronic PLC closed 13.5% short of its 52-week high of $106.33, which the company achieved on November 26th.

The stock outperformed some of its peers, as Johnson & Johnson rose 0.9% to $263.73, Danaher Corp. rose 0.6% to $221.20, and Abbott Laboratories rose 2.23% to $101.82.

Trading volume totaled 36.5 million, compared to the 50-day average of 15.3 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

October 12, 2026 16:34 ET (20:34 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy

Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.

智通财经•2026/10/12 23:31

BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

智通财经•2026/10/12 23:27
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review

Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).

智通财经•2026/10/12 23:11